Shots:

• The P-III (ASCEND) trial evaluates the efficacy & safety of Calquence (100mg, bid) vs IdR or BR in a ratio (1:1) in 310 patients with r/r CLL
• The results showed a PFS benefit @3yrs., 71% reduction in risk of disease progression or death, similar clinical benefits were observed in an exploratory analysis, safety & tolerability were consistent with earlier findings & no new safety signals were observed, treatment discontinuation due to AEs (21%), 65% & 17% of patients on IdR & BR
• The company also presents additional safety analyses from the P-III (ELEVATE-RR) trial of Calquence vs ibrutinib which showed that patients experienced a 37% higher burden of AEs of any grade over Calquence

Ref: AstraZeneca | Image: Mint